

Feb-24-05 16:26 From-pfizer la jolla

+8586788233 T-800 P-008/015 F-884

PC25144A
Correction of Inventorship

EV496345593US

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV496345593US) in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 24th day of February 2005.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
SUZANNE BENEDICT, et al.

Group Art Unit: 1625

Serial No.: 10/754,171

Examiner: AULAKH, CHARANJIT

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN
KINASE INHIBITORS FOR ENHANCING THE
EFFICACY OF ANTI-NEOPLASTIC AGENTS
AND RADIATION THERAPY

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CORRECTION OF INVENTORSHIP IN AN APPLICATION
37 CFR 1.48 (a)

Applicant requests to correct the Inventorship in the above-referenced application pursuant to 37 CFR 1.48(a). Inventors Yong Wang and JinJiang Zhu were inadvertently omitted from the Application. This error occurred without deceptive intent.

As requested in 37 CFR 1.48(a), Applicant attaches the following documents:

1. A statement from each person being added as an inventor that the error in inventorship occurred without deceptive intention on his part;
2. An oath or declaration required by §1.67 (a)(2);
3. The processing fee set forth in §1.17(i); and
4. The written consent of the assignee set forth in §3.73(b).

If any other fees are due in connection with the filing of this response please charge all necessary fees to the deposit account 500329.

Respectfully submitted,

Date: 2/24/05

Reena R. Desai
Reena R. Desai
Agent For Applicants
Registration No. 53,833

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4932 Fax: (858) 678-8233

Feb-24-05 16:30 From-pfizer la jolla
PC25144A
Correction of Inventorship

+8586788233 T-800 P-004/015 F-934

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail (EV496345593US) in an envelope
addressed to: Mail Stop: Commissioner for Patents, PO
Box 1450, Alexandria, VA 22313-1450
on this 24th day of February 2005.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
SUZANNE BENEDICT, et al.

Group Art Unit: 1625

Serial No.: **10/754,171**

Examiner: **AULAKH, CHARANJIT**

Filed: **January 9, 2004**

For: **TRICYCLIC COMPOUNDS PROTEIN
KINASE INHIBITORS FOR ENHANCING THE
EFFICACY OF ANTI-NEOPLASTIC AGENTS
AND RADIATION THERAPY**


Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF INVENTOR IN AN APPLICATION
37 CFR 1.48 (a)(2)

I, Yong Wang, was inadvertently omitted as an inventor in United States Patent Application No. 10/754,171, filed January 9, 2004. This error in inventorship occurred without deceptive intention on my part.

Respectfully submitted,

Date: 2/22/2005


Yong Wang

Feb-24-05 10:00 From-pfizer La Jolla

+8586788233 T-800 2.005/015 F-834

PC25144A
Correction of Inventorship

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail (EV496345593US) in an envelope
addressed to: Commissioner for Patents, PO Box 1450,
Alexandria, VA 22313-1450
on this 23rd day of February 2005.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
SUZANNE BENEDICT, et al.

Group Art Unit: 1625

Serial No.: 10/754,171

Examiner: AULAKH, CHARANJIT

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN
KINASE INHIBITORS FOR ENHANCING THE
EFFICACY OF ANTI-NEOPLASTIC AGENTS
AND RADIATION THERAPY


Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF INVENTOR IN AN APPLICATION
37 CFR 1.48 (a)(2)

I, Jinjiang Zhu, was inadvertently omitted as an inventor in United States Patent Application No. 10/754,171, filed January 9, 2004. This error in inventorship occurred without deceptive intention on my part.

Respectfully submitted,

Date: 2/22/05


Jinjiang Zhu

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Agouron Pharmaceuticals, Inc.Application No./Patent No.: 10/754,171 Filed/Issue Date: 01/09/2004Entitled: Tricyclic Compounds Protein Kinase Inhibitors For Enhancing The Efficacy Of Anti-Neoplastic Agents And Radiation TherapyAgouron Pharmaceuticals, Inc., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 014358, Frame 0202, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

February 16, 2005

Signature

Date

Bryan C. Zielinski

858-622-8864

Printed or Typed Name

Telephone Number

Assistant Secretary

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.